Evaluating the risk-benefit ratio of adjuvant trastuzumab-based therapy for t1a,bN0M0 her2-positive breast carcinomas

M. J. Rodrigues, L. Albiges-sauvin, J. Wassermann, P. H. Cottu

Résultats de recherche: Contribution à un journal › Letter › Revue par des pairs

5 Citations (Scopus)

Accès au document

@article{267a435fc79d4bbcb572fb4cb106003d,

title = "Evaluating the risk-benefit ratio of adjuvant trastuzumab-based therapy for t1a,bN0M0 her2-positive breast carcinomas",

author = "Rodrigues, {M. J.} and L. Albiges-sauvin and J. Wassermann and Cottu, {P. H.}",

year = "2011",

month = jan,

day = "1",

doi = "10.1093/annonc/mdr308",

language = "English",

volume = "22",

pages = "2530",

journal = "Annals of Oncology",

issn = "0923-7534",

number = "11",

}

TY - JOUR

T1 - Evaluating the risk-benefit ratio of adjuvant trastuzumab-based therapy for t1a,bN0M0 her2-positive breast carcinomas

AU - Rodrigues, M. J.

AU - Albiges-sauvin, L.

AU - Wassermann, J.

AU - Cottu, P. H.

PY - 2011/1/1

Y1 - 2011/1/1

UR - http://www.scopus.com/inward/record.url?scp=80155136872&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdr308

DO - 10.1093/annonc/mdr308

M3 - Letter

C2 - 21700734

AN - SCOPUS:80155136872

SN - 0923-7534

VL - 22

SP - 2530

JO - Annals of Oncology

JF - Annals of Oncology

IS - 11

ER -